Grupo de Investigación en Cáncer de Mama
NEONCOBREAST
![Foto de Grupo de Investigación en Cáncer de Mama](/img/uploaded/46084eb269a9135ee7dc8a58bb36982a.jpg)
![Foto de University of Chinese Academy of Sciences](/img/noimage_org.png)
University of Chinese Academy of Sciences
Pekín, ChinaPublicaciones en colaboración con investigadores/as de University of Chinese Academy of Sciences (1)
2022
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268